ATE481397T1 - Modulatoren des östrogenrezeptors - Google Patents

Modulatoren des östrogenrezeptors

Info

Publication number: ATE481397T1
Authority: AT; Austria
Prior art keywords: estrogen; compounds; estrogen receptor; modulators; functioning
Prior art date: 2002-04-24

Application number

AT03736470T

Other languages

English (en)

Inventor

Frank Dininno

Timothy BLIZZARD

Jerry Morgan

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-24

Filing date

2003-04-18

Publication date

2010-10-15

2003-04-18 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE481397T1 publication Critical patent/ATE481397T1/de

Links

102000015694 estrogen receptors Human genes 0.000 title abstract 2
108010038795 estrogen receptors Proteins 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000010392 Bone Fractures Diseases 0.000 abstract 1
206010065687 Bone loss Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
201000009273 Endometriosis Diseases 0.000 abstract 1
208000033830 Hot Flashes Diseases 0.000 abstract 1
206010060800 Hot flush Diseases 0.000 abstract 1
206010021639 Incontinence Diseases 0.000 abstract 1
238000008214 LDL Cholesterol Methods 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
210000000481 breast Anatomy 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000000845 cartilage Anatomy 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
230000001149 cognitive effect Effects 0.000 abstract 1
230000006735 deficit Effects 0.000 abstract 1
230000007850 degeneration Effects 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
239000002834 estrogen receptor modulator Substances 0.000 abstract 1
201000000079 gynecomastia Diseases 0.000 abstract 1
201000010260 leiomyoma Diseases 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
210000002307 prostate Anatomy 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
208000010579 uterine corpus leiomyoma Diseases 0.000 abstract 1
201000007954 uterine fibroid Diseases 0.000 abstract 1
210000004291 uterus Anatomy 0.000 abstract 1
210000004509 vascular smooth muscle cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

AT03736470T 2002-04-24 2003-04-18 Modulatoren des östrogenrezeptors ATE481397T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37523702P	2002-04-24	2002-04-24
PCT/US2003/012103 WO2003091239A1 (en)	2002-04-24	2003-04-18	Estrogen receptor modulators

Publications (1)

Publication Number	Publication Date
ATE481397T1 true ATE481397T1 (de)	2010-10-15

Family

ID=29270611

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03736470T ATE481397T1 (de)	2002-04-24	2003-04-18	Modulatoren des östrogenrezeptors

Country Status (13)

Country	Link
US (1)	US7138426B2 (de)
EP (1)	EP1501819B1 (de)
JP (1)	JP4554219B2 (de)
AT (1)	ATE481397T1 (de)
AU (1)	AU2003237084C1 (de)
CA (1)	CA2484038C (de)
CY (1)	CY1111195T1 (de)
DE (1)	DE60334202D1 (de)
DK (1)	DK1501819T3 (de)
ES (1)	ES2350446T3 (de)
PT (1)	PT1501819E (de)
SI (1)	SI1501819T1 (de)
WO (1)	WO2003091239A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006065599A1 (en) *	2004-12-17	2006-06-22	Bionovo, Inc.	Method of using extracts of epimedium species
AU2006307046A1 (en) *	2005-10-27	2007-05-03	Msd K.K.	Novel benzoxathiin derivative
CN101389623A (zh) *	2006-02-28	2009-03-18	阿斯利康(瑞典)有限公司	吲哚衍生物的新的盐及其在医药中的用途
CA2656067C (en) *	2006-06-23	2014-08-12	Radius Health, Inc.	Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20080119444A1 (en) *	2006-11-16	2008-05-22	Steven Lehrer	Methods and compositions for the treatment of cancer
KR101638035B1 (ko)	2007-01-22	2016-07-11	지티엑스, 인코포레이티드	핵 수용체에 결합하는 물질
US9604931B2 (en)	2007-01-22	2017-03-28	Gtx, Inc.	Nuclear receptor binding agents
US9623021B2 (en) *	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
MX2010004195A (es)	2007-10-16	2010-06-02	Repros Therapeutics Inc	Trans-clomifeno para el sindrome metabolico.
US7902147B2 (en)	2007-11-05	2011-03-08	Duke University	Chronic lymphocytic leukemia prognosis and treatment
CN101945853B (zh)	2007-12-21	2014-08-20	配体药物公司	选择性雄激素受体调节剂(sarm)及其应用
US20100087402A1 (en) *	2008-09-29	2010-04-08	Vivus, Inc.	Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
PL2568806T3 (pl)	2010-05-12	2017-03-31	Radius Health, Inc.	Schematy lecznicze
EP3205648A1 (de) *	2010-06-10	2017-08-16	Seragon Pharmaceuticals, Inc.	Östrogenrezeptormodulatoren und verwendungen davon
US8853423B2 (en)	2010-06-17	2014-10-07	Seragon Pharmaceuticals, Inc.	Indane estrogen receptor modulators and uses thereof
AU2011312490B2 (en)	2010-09-28	2015-06-25	Radius Pharmaceuticals, Inc.	Selective androgen receptor modulators
CA2819299A1 (en)	2010-12-24	2012-06-28	Merck Sharp & Dohme B.V.	N-substituted azetidine derivatives
EP2791132A4 (de)	2011-12-14	2015-08-05	Seragon Pharmaceuticals Inc	Östrogenrezeptormodulatoren und verwendungen davon
BR112014014767A2 (pt)	2011-12-16	2017-06-13	Olema Pharmaceuticals Inc	novos compostos de benzopirano, composições e usos dos mesmos
MX2014009322A (es)	2012-02-29	2014-11-10	Repros Therapeutics Inc	Terapia de combinacion para el tratamiento de la deficiencia androgenica.
JP2016516004A (ja)	2013-02-22	2016-06-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病二環式化合物
US9421264B2 (en)	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (es)	2014-03-28	2023-04-28	Univ Duke	Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US11633382B2 (en)	2015-11-10	2023-04-25	Paracrine Therapeutics Ab	Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
SG11201806829TA (en)	2016-02-15	2018-09-27	Sanofi Sa	6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
WO2017223115A1 (en)	2016-06-22	2017-12-28	Radius Health, Inc.	Ar+ breast cancer treatment methods
EP3541809B1 (de) *	2016-11-17	2025-06-25	Sanofi	Substituierte n-(3-fluorpropyl)-pyrrolidin-verbindungen, verfahren zu deren herstellung und therapeutische verwendungen davon
EP3565542B1 (de)	2017-01-05	2024-04-10	Radius Pharmaceuticals, Inc.	Polymorphe formen von rad1901-2hcl
WO2018138739A1 (en)	2017-01-27	2018-08-02	Sun Pharma Advanced Research Company Limited	Novel antiestrogenic heterocyclic compounds
EP3434272A1 (de)	2017-07-25	2019-01-30	Sanofi	Kombination aus palbociclib und 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsäure
SG11202006942WA (en) *	2018-01-22	2020-08-28	Radius Pharmaceuticals Inc	Estrogen receptor-modulating compounds
SG11202013177WA (en)	2018-07-04	2021-01-28	Radius Pharmaceuticals Inc	Polymorphic forms of rad 1901-2hcl
DK3847157T3 (da)	2018-09-07	2022-08-08	Sanofi Sa	Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
US12441745B2 (en)	2019-02-12	2025-10-14	Radius Pharmaceuticals, Inc.	Processes and compounds
AU2020257397B2 (en)	2019-04-19	2026-02-26	Ligand Pharmaceuticals Inc.	Crystalline forms and methods of producing crystalline forms of a compound
WO2021016254A1 (en)	2019-07-22	2021-01-28	Radius Pharmaceuticals, Inc.	Estrogen receptor-modulating compounds
WO2021063967A1 (en)	2019-10-01	2021-04-08	Sanofi	Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en)	2019-12-09	2021-06-17	Sanofi	Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh)	2020-02-27	2021-12-16	法商賽諾菲公司	包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL302152B1 (en)	2020-10-19	2026-07-01	Sanofi Sa	6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302153B1 (en)	2020-10-19	2026-07-01	Sanofi Sa	6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1096458C (zh)	1996-02-24	2002-12-18	巴斯福股份公司	2－杂芳酰基环己烷－1,3－二酮
US5985306A (en) *	1996-10-28	1999-11-16	Novo Nordisk A/S	(+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
FR2762598A1 (fr)	1997-04-25	1998-10-30	Adir	Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennnent
US6465445B1 (en) *	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EE200300153A (et)	2000-10-19	2003-06-16	Merck & Co., Inc.	Östrogeeni retseptori modulaatorid, farmatseutiline kompositsioon ja selle valmistamismeetod
EP1328522A2 (de)	2000-10-19	2003-07-23	Merck & Co., Inc.	Modulatoren des östrogen-rezeptors
US6750213B2 (en) *	2000-10-19	2004-06-15	Merck & Co., Inc.	Estrogen receptor modulators
US20030225132A1 (en) *	2002-04-11	2003-12-04	Dininno Frank P.	Estrogen receptor modulators

2003
- 2003-04-18 AT AT03736470T patent/ATE481397T1/de active
- 2003-04-18 SI SI200331909T patent/SI1501819T1/sl unknown
- 2003-04-18 WO PCT/US2003/012103 patent/WO2003091239A1/en not_active Ceased
- 2003-04-18 ES ES03736470T patent/ES2350446T3/es not_active Expired - Lifetime
- 2003-04-18 AU AU2003237084A patent/AU2003237084C1/en not_active Ceased
- 2003-04-18 EP EP03736470A patent/EP1501819B1/de not_active Expired - Lifetime
- 2003-04-18 CA CA2484038A patent/CA2484038C/en not_active Expired - Fee Related
- 2003-04-18 PT PT03736470T patent/PT1501819E/pt unknown
- 2003-04-18 US US10/512,172 patent/US7138426B2/en not_active Expired - Lifetime
- 2003-04-18 DE DE60334202T patent/DE60334202D1/de not_active Expired - Lifetime
- 2003-04-18 JP JP2003587798A patent/JP4554219B2/ja not_active Expired - Fee Related
- 2003-04-18 DK DK03736470.0T patent/DK1501819T3/da active
2010
- 2010-12-13 CY CY20101101150T patent/CY1111195T1/el unknown

Also Published As

Publication number	Publication date
SI1501819T1 (sl)	2011-01-31
WO2003091239A1 (en)	2003-11-06
JP2005529136A (ja)	2005-09-29
EP1501819A4 (de)	2006-06-21
EP1501819B1 (de)	2010-09-15
CY1111195T1 (el)	2015-06-11
DK1501819T3 (da)	2011-01-10
EP1501819A1 (de)	2005-02-02
US20050234245A1 (en)	2005-10-20
ES2350446T3 (es)	2011-01-24
AU2003237084C1 (en)	2009-03-26
CA2484038C (en)	2011-10-18
PT1501819E (pt)	2010-11-11
CA2484038A1 (en)	2003-11-06
DE60334202D1 (de)	2010-10-28
AU2003237084B2 (en)	2008-11-20
AU2003237084A1 (en)	2003-11-10
US7138426B2 (en)	2006-11-21
JP4554219B2 (ja)	2010-09-29

Legal Events

Date

Code

Title

Description

2011-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1501819

Country of ref document: EP

Publication	Publication Date	Title
DE60334202D1 (de)	2010-10-28	Modulatoren des östrogenrezeptors
ATE524170T1 (de)	2011-09-15	Östrogenrezeptor modulatoren
WO2002091993A3 (en)	2003-03-20	Estrogen receptor modulators
DE60120746D1 (de)	2006-07-27	Östrogenrezeptormodulatoren
MX2007006878A (es)	2007-06-22	Moduladores del receptor de estrogeno.
TW200631933A (en)	2006-09-16	Estrogen receptor modulators
WO2004073612A3 (en)	2004-10-28	Estrogen receptor modulators
WO2002032377A3 (en)	2002-08-22	Estrogen receptor modulators
WO2004091488A3 (en)	2005-04-07	Estrogen receptor modulators
WO2007062230A3 (en)	2007-09-20	Nuclear receptor binding agents
WO2002032373A3 (en)	2002-07-04	Estrogen receptor modulators
AU2003288644A1 (en)	2004-10-25	Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof
WO2006081152A3 (en)	2007-02-08	Estrogen receptor modulators
EP1943224A4 (de)	2009-07-15	Östrogenrezeptormodulatoren
WO2005097141A3 (en)	2006-03-23	Estrogen receptor modulators
AR039282A1 (es)	2005-02-16	Moduladores de receptores de estrogeno
WO2004073610A3 (en)	2004-11-25	Estrogen receptor modulators
ATE301629T1 (de)	2005-08-15	Estrogenrezeptorliganden und verfahren
WO2002058639A3 (en)	2002-10-24	Pyranoflavonoid compounds and their use as estrogen receptor modulators
WO2004026887A3 (en)	2005-02-24	Estrogen receptor modulators
WO2008057309A3 (en)	2008-08-07	Estrogen receptor modulators
WO2009059806A3 (en)	2009-10-29	Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine
MA32477B1 (fr)	2011-07-03	Derives estratrienes comprenant des bioisosteres heterocycliques pour le cycle a phenolique
DOP2002000384A (es)	2003-09-30	Moduladores de receptores estrogenicos.
DOP2005000224A (es)	2006-06-15	Moduladores de los receptores de estrogeno